Showing 441-450 of 450 results for "".

• Alcon Announces US Launch of Systane PRO PF for Dry Eye Relief
  https://modernod.com/news/alcon-announces-us-launch-of-systane-pro-pf-for-dry-eye-relief/2482678/
  Alcon has launched Systane PRO Preservative-Free (PF) in the US, the latest addition to its over-the-counter dry eye portfolio. According to Alcon, Systane PRO PF is the longest-lasting eye drop in the Systane lineup, offering a tr
• Alcon to Showcase New Data and Innovation to Support Ophthalmic Surgical Teams at ESCRS
  https://modernod.com/news/alcon-to-showcase-new-data-and-innovation-to-support-ophthalmic-surgical-teams-at-escrs/2481815/
  Alcon will present a lineup of scientific data at the 41st Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) Sept. 8-12 in Vienna, Austria. Alcon will showcase product updates designed to deliver patient outcomes and operational efficiencies for ophthalmologists an
• RG6501 (OpRegen) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in GA
  https://modernod.com/news/rg6501-opregen-phase-12a-clinical-results-support-the-potential-for-opregen-to-slow-stop-or-reverse-disease-progression-in-ga/2481569/
  Lineage Cell Therapeutics announced that results from imaging analyses of structural changes and visual data from a phase 1/2a clinical study of RG6501 (OpRegen), were presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2023). The presentation
• RG6501 (OpRegen) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
  https://modernod.com/news/rg6501-opregen-phase-12a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit/2481476/
  Lineage Cell Therapeutics announced that results from a phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the 
• Genentech Launches Phase 2a Study of RG6501 (OpRegen) in Patients With Geographic Atrophy
  https://modernod.com/news/genentech-launches-phase-2a-study-of-rg6501-opregen-in-patients-with-geographic-atrophy/2481274/
  Lineage Cell Therapeutics announced that its partner Genentech has 
• RG6501 (OpRegen) Full Phase 1/2a Results to Be Presented at ARVO Annual Meeting
  https://modernod.com/news/rg6501-opregen-full-phase-12a-results-to-be-presented-at-arvo-annual-meeting/2480697/
  Lineage Cell Therapeutics announced that full results from a phase 1/2a clinical study of RG6501 (OpRegen), a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be presented at the 2022 Associ
• Dell, HP, Lenovo and Acer to Announce New Eyesafe Products at the Blue Light Summit 2020
  https://modernod.com/news/dell-hp-lenovo-and-acer-to-announce-new-eyesafe-products-at-the-blue-light-summit-2020/2478378/
  Eyesafe, UnitedHealthcare Vision, and TÜV Rheinland Group announced the dates and registration details as well as the initial lineup of companies and thought leaders participating in the Blue Light Summit 2020. This year’s event will be held on Oct. 15, 2020. D
• Vision Expo East Announces Speakers and Experiences for The Bridge and Innovation Stage
  https://modernod.com/news/vision-expo-east-announces-speakers-and-experiences-for-the-bridge-and-innovation-stage/2477341/
  Vision Expo announced the series of events and speakers planned for The Bridge and Innovation Stage at the 2020 event in New York City. In keeping with Vision Expo’s renewed focus on discovery, experience, and connection, attendees can expect a robust lineup of industry experts, creative luminari
• Allergan Teams Up With Super Bowl MVP Von Miller to Raise Awareness of Glaucoma’s Impact on Daily Living
  https://modernod.com/news/allergan-teams-up-with-super-bowl-mvp-von-miller-to-raise-awareness-of-glaucomas-impact-on-daily-living/2477236/
  Allergan announced a partnership with Von Miller, Super Bowl MVP, Denver Broncos linebacker, and advocate for healthy vision, to shine a light on the millions of people living with glaucoma. As an ambassador for the ‘My Glaucoma’ campaign, Mr. Miller wil
• Canon Xephilio OCT-A1 Device Receives FDA 510(k) Clearance
  https://modernod.com/news/canon-xephilio-oct-a1-device-receives-fda-510k-clearance/2476889/
  Expanding the company’s lineup of eye care product offerings, Canon USA announced the new intuitive Xephilio OCT-A1 device. This device features automated acquisition functionality, which makes it easy to use, allowing healthcare professionals to obtain high

• Previous
• 1
• 2
• …
• 43
• 44
• 45
• Next